FFA
ABEO icon

Farther Finance Advisors’s Abeona Therapeutics ABEO Stock Holding History

Farther Finance Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.12K Buy
666
+48
+8% +$264 ﹤0.01% 4892
2026
Q1 		$2.83K Sell
618
-1,506
-71% -$7.53K ﹤0.01% 4759
2025
Q4 		$11.2K Buy
2,124
+1,401
+194% +$7.05K ﹤0.01% 3832
2025
Q3 		$3.82K Buy
723
+343
+90% +$2.17K ﹤0.01% 3880
2025
Q2 		$2.16K Buy
+380
New +$2.16K ﹤0.01% 3673

Other funds holding ABEO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Farther Finance Advisors's ABEO Position: Q2 2026 in Review

Farther Finance Advisors increased its Abeona Therapeutics (ABEO) stake by 7.8% in Q2 2026, buying an estimated $264 and bringing the position to 666 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #4892.

Farther Finance Advisors first reported a position in ABEO in Q2 2025 and has held it in 5 quarters since. The position peaked at $11.2K in Q4 2025. 6 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Farther Finance Advisors held 666 shares of Abeona Therapeutics worth $4.12K as of Q2 2026.
  • Farther Finance Advisors bought 48 Abeona Therapeutics shares in Q2 2026, an estimated $264.
  • Abeona Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4892 holding.
  • Farther Finance Advisors first reported a position in Abeona Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Farther Finance Advisors's Abeona Therapeutics position peaked at $11.2K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.